Incidence and risk factors of rituximab-associated hypogammaglobulinemia in patients with complicated nephrotic syndrome

Volume: 37, Issue: 5, Pages: 1057 - 1066
Published: Oct 4, 2021
Abstract
Hypogammaglobulinemia is a major adverse event after rituximab treatment; however, the precise incidence and risk factors are unclear in complicated steroid-dependent or frequently relapsing nephrotic syndrome (SDNS/FRNS) patients.This was a single-center, retrospective, observational study. Patients who received a single dose of rituximab for complicated SDNS or FRNS between February 2007 and May 2019 were enrolled. Serum IgG levels were...
Paper Details
Title
Incidence and risk factors of rituximab-associated hypogammaglobulinemia in patients with complicated nephrotic syndrome
Published Date
Oct 4, 2021
Volume
37
Issue
5
Pages
1057 - 1066
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.